Tempus AI Surges on Vaccine Data Amid Insider Selling

Tempus AI's stock has surged by roughly 38 percent in seven days, with insiders quietly selling shares during this period.

The rally is attributed to Phase-3 data from Moderna and Merck on a personalized melanoma vaccine, which validated the precision-oncology infrastructure thesis that Tempus AI sequences and analyzes tumor data for.

CEO Eric Lefkofsky sold 133,000 shares at €49.61 just before the stock jumped 24 percent, while CFO James Rogers disposed of nearly 49,000 shares and data chief Ryan Fukushima shed over 41,000 shares.

The insider selling pattern is a standard practice across US technology companies with heavy equity compensation programs, where executives must sell to cover tax liabilities when restricted stock units vest.